Loading...
XWAR
SLV
Market cap236mUSD
Dec 05, Last price  
46.70PLN
1D
0.86%
1Q
45.03%
IPO
119.25%
Name

Selvita SA

Chart & Performance

D1W1MN
XWAR:SLV chart
P/E
P/S
2.51
EPS
Div Yield, %
Shrs. gr., 5y
28.39%
Rev. gr., 5y
62.22%
Revenues
342m
-1.43%
41,028,64148,133,12754,573,74070,678,63930,443,469137,356,285310,920,815407,462,000346,957,000342,007,000
Net income
-6m
L
6,269,8112,720,2113,926,48510,496,4885,523,00217,998,07814,899,00030,309,00069,878,000-6,098,000
CFO
64m
-18.88%
-16,429,766-6,280,11210,538,65911,595,2824,299,16429,356,20387,472,02675,430,00078,980,00064,069,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.
IPO date
Oct 16, 2019
Employees
847
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT